Hellman KB - Search Results

1

Prevalence of viremia in human immunodeficiency virus-infected patients with renal disease.

Kimmel PL, VedBrat SS, Pierce PF, Umana WO, Shepherd L, Verme DA, Hirsch RP, Hellman KB. Kimmel PL, et al. Among authors: hellman kb. Arch Intern Med. 1995 Aug 7-21;155(15):1578-84. Arch Intern Med. 1995. PMID: 7618979

2

Quantitation of human immunodeficiency virus (HIV) with respect to disease stage and zidovudine (AZT) therapy.

Ved Brat SS, Shepherd LP, Boulberhane A, Pierce PF, Hellman KB. Ved Brat SS, et al. Among authors: hellman kb. AIDS Res Hum Retroviruses. 1992 Jul;8(7):1271-81. doi: 10.1089/aid.1992.8.1271. AIDS Res Hum Retroviruses. 1992. PMID: 1520539

3

Human B-lymphotropic virus (human herpesvirus-6).

Ablashi DV, Josephs SF, Buchbinder A, Hellman K, Nakamura S, Llana T, Lusso P, Kaplan M, Dahlberg J, Memon S, et al. Ablashi DV, et al. J Virol Methods. 1988 Sep;21(1-4):29-48. doi: 10.1016/0166-0934(88)90050-x. J Virol Methods. 1988. PMID: 2846617 Review.

4

In vitro inhibition of human herpesvirus-6 by phosphonoformate.

Streicher HZ, Hung CL, Ablashi DV, Hellman K, Saxinger C, Fullen J, Salahuddin SZ. Streicher HZ, et al. J Virol Methods. 1988 Sep;21(1-4):301-4. doi: 10.1016/0166-0934(88)90075-4. J Virol Methods. 1988. PMID: 2972736

5

Enhancing Tissue Engineering and Regenerative Medicine Product Commercialization: The Role of Science in Regulatory Decision-Making for the TE/RM Product Development.

Bertram TA, Johnson PC, Tawil BJ, Van Dyke M, Hellman KB. Bertram TA, et al. Among authors: hellman kb. Tissue Eng Part A. 2015 Oct;21(19-20):2476-9. doi: 10.1089/ten.TEA.2015.0136. Epub 2015 Sep 8. Tissue Eng Part A. 2015. PMID: 26222734

6

Awareness of the role of science in the FDA regulatory submission process: a survey of the TERMIS-Americas membership.

Johnson PC, Bertram TA, Carty NR, Hellman KB, Tawil BJ, Van Dyke M. Johnson PC, et al. Among authors: hellman kb. Tissue Eng Part A. 2014 Jun;20(11-12):1565-82. doi: 10.1089/ten.TEA.2014.0112. Tissue Eng Part A. 2014. PMID: 24665855

7

Bench to business: a framework to assess technology readiness.

Rahmany MB, Tawil BJ, Hellman KB, Johnson PC, Van Dyke M, Bertram T. Rahmany MB, et al. Among authors: hellman kb. Tissue Eng Part A. 2013 Nov;19(21-22):2314-7. doi: 10.1089/ten.tea.2013.0474. Tissue Eng Part A. 2013. PMID: 24059603 No abstract available.

8

Enhancing tissue engineering/regenerative medical product commercialization: the role of science in regulatory decision making for tissue engineering/regenerative medicine product development.

Bertram TA, Johnson PC, Tawil B, Van Dyke M, Hellman KB. Bertram TA, et al. Among authors: hellman kb. Tissue Eng Part A. 2013 Nov;19(21-22):2313. doi: 10.1089/ten.tea.2013.0536. Epub 2013 Oct 11. Tissue Eng Part A. 2013. PMID: 24059530 No abstract available.

9

Commercialization of regenerative products: the academic/industry partnership.

Bayon Y, Ellison S, Vertès A, Ahmed A, Coury AJ, Campion C, Bertram TA, Hellman KB. Bayon Y, et al. Among authors: hellman kb. Tissue Eng Part B Rev. 2014 Aug;20(4):243-5. doi: 10.1089/ten.TEB.2012.0683. Epub 2013 Jul 10. Tissue Eng Part B Rev. 2014. PMID: 23281665 Review. No abstract available.

10

The regulatory imperative: international perspective.

Bertram T, Hellman KB, Bayon Y, Ellison S, Wilburn S. Bertram T, et al. Among authors: hellman kb. Tissue Eng Part B Rev. 2013 Jun;19(3):191-3. doi: 10.1089/ten.TEB.2012.0654. Epub 2013 Jan 30. Tissue Eng Part B Rev. 2013. PMID: 23216282 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

42 results

Search Page